Novo Nordisk outlines strategic priorities at Capital Markets Day 2026

Novo Nordisk is hosting a Capital Markets Day in London, providing an update on its corporate strategy and strategic ambitions through 2030. Throughout the day, members of Novo’s senior management will present on corporate strategy, research and development strategy, priorities across therapy areas, commercial strategy in the U.S. and international markets, global manufacturing and supply, and financial performance.

The strategic ambitions for 2030 fall into three main areas.

On growing and diversifying its pipeline, Novo aims to launch more than five multi-blockbuster products by 2030 and generate over 150 billion Danish kroner in pipeline sales by 2035. The company is targeting at least five Phase 3 programs in obesity and diabetes, along with at least five additional Phase 3 programs spanning other therapy areas.

On driving sustainable growth, Novo intends to deliver a revenue compound annual growth rate between 2026 and 2030 in line with its industry peers, while scaling manufacturing capacity to serve up to ten times more people living with obesity through oral GLP-1 treatments. The company is targeting service to more than 60 million patients globally by 2030.

On delivering attractive returns, Novo plans to maintain a broadly stable operating margin alongside an attractive dividend per share.

All sessions from the Capital Markets Day are being webcast live, with a replay to be made available afterward in the investor section of novonordisk.com. Presentation materials from the event will also be posted there throughout the day.

Novo Nordisk describes itself as a global healthcare company built on the belief that lasting health starts now. For more than a century, the company has combined scientific expertise with an understanding of people’s everyday lives, developing treatments and support intended to help millions of people make progress they can see, feel, and sustain, both now and going forward. Approximately 66,000 employees worldwide work toward the company’s stated purpose of driving change for lasting health. Through its partnerships, programs, and investments, Novo says it is working to prevent disease, broaden access to treatment, and reduce its environmental footprint in order to help more people live healthier lives.

This press release may contain forward-looking statements relating to Novo Nordisk’s operating, research and development, financial, and sustainability performance, as well as that of the broader industry in which it operates. Such statements inherently involve risks, uncertainties, and assumptions, both general and specific, and actual outcomes may differ materially from what is expressed or implied.

---

---

Related Topics and Keywords

Capital Markets Day 2026, Novo Nordisk